Catalyst
Slingshot members are tracking this event:
On August 10th, FDA to give PDUFA decision on Amgen's (AMGN) BLINCYTO (blinatumomab) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 11, 2017
Occurred Source:
http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2285903
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Acute Lymphoblastic Leukemia, Blincyto® (blinatumomab), Pdufa, Phase 3 Tower Study
